The publication aims to compare the risk of multiple sclerosis in anti-tumor necrosis factor alpha users with non-users among rheumatic disease or inflammatory bowel disease patients.
Citation
Li L, Aviña-Zubieta JA, Bernstein C, Kaplan GG, Tremlett H, Xie H, Peña-Sánchez JN, Marrie RA, Etminan M. The Risk of Multiple Sclerosis Among Users of Anti-tumor Necrosis Factor Alpha in four Canadian provinces: A Population-Based Study. Neurology. 2022; (Published ahead).